Altimmune is trading 5.5% down at $3.02 amid broad risk-off sentiment weighing on growth-oriented stocks.
- Elevated Treasury yields, inflation concerns and a broader equity sell-off are pressuring markets; biotechnology is also weakening.
- No clear company-specific catalyst was identified for September 24, 2026, so confidence in the market-driven explanation is medium.
- The latest listed company update concerned investor conference participation; its most recent substantive business update was published in August.